Prescient Therapeutics – Interview with Dr Allen Ebens
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving...
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving...
Special Report: A form of immunotherapy that involves modifying a patient’s white blood cells so...
Today, we will acquaint you with the product pipeline of ASX-listed clinical-stage biotechnology company Prescient Therapeutics...
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each...
When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2...
Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline...
Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking...
Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the...
Locally-listed small cap biotech company Prescient Therapeutics hopes to shift the conversation around cancer from treatments to...
ASX-listed clinical-stage company Prescient Therapeutics Limited (ASX:PTX) is well-known for developing breakthrough targeted and personalised medicines approaches...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.